The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain ...
The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...
Not content with buying up a big chunk of the world’s generics market with its $40.5 billion merger with Actavis, Teva is muscling in on biosimilars with a deal with South Korea’s Celltrion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback